RBRC01477, B6.129S6-Ptprj<tm1Taka>/SataRbrc

RBRC No. RBRC01477
Type Targeted MutationCartagena
Species Mus musculus
Strain name B6.129S6-Ptprj<tm1Taka>/SataRbrc
Former Common name CD148/DEP-1 KO/PTPRJ, CD148 KO
H-2 Haplotype No Data
Donor strain 129S6/SvEvTac via TL1/TL-1 ES cell line
Background strain No Data
1 Appearance black
Genotype a/a B/B C/C
Strain development Developed by Dr Takamune Takahashi at Vanderbilt University Medical Center in 2003. A targeting construct containing EGFP and neo was transfered into ES cells to disrupt Ptprj gene. GFP fluorescence was not detected in mutant mice.
Strain description B6.129S6-Ptprj<tm1Taka>. Protein tyrosine phospatase, receptor type J (CD148) is a member of the receptor tyrosine phosphatase family playing an important role in cell growth, differentiation, and development. Homozygous Ptprj<tm1Taka> mutant mice were embryonic lethal due to abnormal cardiovascular system morphology.
Colony maintenance Backcross to C57BL/6 (Heterozygote x C57BL/6JJcl)
Health Report No Data
Gene Details
Promoter No Data
1 Symbol Ptprj
Symbol name protein tyrosine phosphatase, receptor type, J
Chromosome 2
Common name BET, Byp, CD148, DEP-1, Ptpb2, PTPbeta2, Scc-1, Scc1
Symbol description No Data
2 Symbol GFP
Symbol name Green Fluorescent Protein (Jellyfish)
Chromosome 2
Common name No Data
Symbol description No Data
3 Symbol loxP
Symbol name phage P1 loxP
Chromosome 2
Common name No Data
Symbol description No Data
Promoter herpes simplex virus thymidine kinase promoter (HSV tk promoter)
4 Symbol neo
Symbol name neomycin resistance gene (E. coli)
Chromosome 2
Common name neo; neomycin;
Symbol description No Data
References Mol Cell Biol. 2003 Mar;23(5):1817-31.

A mutant receptor tyrosine phosphatase, CD148, causes defects in vascular development.
Research applications Cre/loxP system,
Fluorescent Proteins/lacZ System
Specific Term and Conditions The following terms and conditions will be requested by the DEPOSITOR.
The RECIPIENT of BIOLOGICAL RESOURCE shall obtain a prior written consent on use of it from the DEPOSITOR.
In publishing the research results obtained by use of the BIOLOGICAL RESOURCE, a citation of the following literature(s) designated by the DEPOSITOR is requested.
Mol. Cell. Biol., 23, 1817-1831 (2003).
In publishing the research results to be obtained by use of the BIOLOGICAL RESOURCE, an acknowledgment to the DEPOSITOR is requested.
The RECIPIENT agrees to include the DEPOSITOR as a co-author in any publications resulted by the use of the BIOLOGICAL RESOURCE during the first 2 years after deposition by the DEPOSITOR to the RIKEN BRC.
The RECIPIENT should contact the DEPOSITOR in the case of application for any patents or commercial use with the results from the use of the BIOLOGICAL RESOURCE.
Additional information
1 GFP Transfer License (Japanese / English)
Please fill in the Schedule A, and submit two signed copies to us together with two signed copies of RIKEN BRC’s MTA. Please also read Schedule B.
Lab HP (Japanese)
2 Genotyping protocol <PCR>
Depositor Satake, Masanobu (Institute of Development, Aging and Cancer, Tohoku University) Satake, Masanobu
Strain Status /
(Expected delivery)

Cryopreserved embryos : Within 1 month
Recovered litters from cryopreserved embryos : 2-4 months

Cryopreserved sperm : Within 1 month
Recovered litters from cryopreserved sperm : 2-4 months